News

The awarding of the patent thus allows to analyze by high-throughput processes to which extent such drug candidates block the export of viral messenger RNA from the cell

Each of the 39 separate Blue Cross and Blue Shield companies, acting independently, now has the opportunity to enter into an ancillary contract to access FAMILION LQTS tests

Cope also served for a number of years as the Ernest W. Volwiler Fellow and head, cancer and AIDS research effort for Abbot Laboratories-Ross Division. Cope is active

The data show that treatment with cyclopamine, the natural product foundation of IPI-926, in animals bearing grafts of primary ovarian cancer resulted in significant tumor growth inhibition compared

Dr Rava comes to Artemis after 16 years at Affymetrix where he was a scientific co-founder and most recently senior vice president of R&D. Dr Rava has received

The company believes the decline in sales is related to customers tumbling their capital expenditures as a result of the changes in the global economy. The anticipated revenue

Since joining 3SBio in October 2008, Mr Tan has been acting as the financial advisor for the company, providing advice on the company’s capital market initiatives and overseeing

Mr Larochelle will remain on the board of directors of Adaltis and will ensure a smooth executive leadership transition, working with Mr Bambic in his new role. Most

The 500mg single-dose vial expands Sagent’s existing line of cefazolin products beyond the 1gm single-dose vials and 10gm pharmacy bulk package vials launched in March 2008. All doses